Ignite Creation Date:
2025-12-24 @ 7:01 PM
Ignite Modification Date:
2025-12-29 @ 11:07 PM
Study NCT ID:
NCT05661357
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-17
First Post:
2022-11-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression
Sponsor:
Zhongnan Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-01-01
Start Date Type:
ACTUAL
Primary Completion Date:
2025-01-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-11-08
First Submit QC Date:
None
Study First Post Date:
2022-12-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-16
Last Update Post Date:
2024-04-17
Last Update Post Date Type:
ACTUAL